Aceso Life Science Group Limited AI Stock Analysis
Want to see HK:0474 full AI Analyst Report?
Aceso Life Science Group Limited (0474) AI Stock Analysis
Aceso Life Science Group Limited
(HKEX:0474)
The overall score is constrained by weak and volatile financial performance, with shrinking revenue, high leverage, and thin cash support for reported profits weighing heavily on the assessment. Technicals are relatively favorable, as the stock is in a strong short-term uptrend, though overextended momentum limits conviction and adds near-term downside risk. Valuation appears inexpensive on headline P/E, but the low multiple is tempered by poor earnings quality and the lack of a dividend, suggesting the market is pricing in elevated business and balance-sheet risk.
Aceso Life Science Group Limited (0474) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.23B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.32M
- Price to Earnings (P/E)
- 3.0
- Beta (1Y)
- 0.32
- Revenue Growth
- -57.48%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 28
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Rental & Leasing Services
Aceso Life Science Group Limited Business Overview & Revenue Model
Company Description
Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of co...
Aceso Life Science Group Limited Financial Statement Overview
Summary
Revenue has shrunk sharply with high volatility, recent profit relies heavily on non-operating or non-cash gains, leverage remains elevated, and cash flows are weak and erratic relative to reported earnings, leaving the turnaround fragile.
Income Statement
35NegativeBalance Sheet
30NegativeCash Flow
32Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 64.00M | 64.00M | 195.00M | 11.00M | 312.00M | 315.00M |
| Gross Profit | 64.00M | 54.00M | 90.00M | -100.00M | 141.00M | 162.00M |
| EBITDA | -776.00M | -297.00M | -860.00M | -630.00M | -21.00M | -359.00M |
| Net Income | 338.00M | 338.00M | -895.00M | -462.00M | -264.00M | -370.00M |
Balance Sheet | ||||||
| Total Assets | 1.79B | 1.79B | 3.24B | 4.79B | 6.30B | 6.26B |
| Cash, Cash Equivalents and Short-Term Investments | 345.00M | 345.00M | 207.00M | 466.00M | 602.00M | 717.00M |
| Total Debt | 1.19B | 1.19B | 2.30B | 2.74B | 2.34B | 3.01B |
| Total Liabilities | 1.33B | 1.33B | 2.50B | 2.97B | 3.73B | 3.44B |
| Stockholders Equity | 457.00M | 457.00M | 12.00M | 921.00M | 1.55B | 2.00B |
Cash Flow | ||||||
| Free Cash Flow | -79.00M | 20.00M | 15.00M | -48.00M | 175.00M | 259.00M |
| Operating Cash Flow | -79.00M | 20.00M | 17.00M | -37.00M | 222.00M | 316.00M |
| Investing Cash Flow | 682.00M | 674.00M | 337.00M | 472.00M | -120.00M | -441.00M |
| Financing Cash Flow | -578.00M | -681.00M | -587.00M | 117.00M | -98.00M | 126.00M |
Aceso Life Science Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0474, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.14, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.33 is Neutral, neither overbought nor oversold. The STOCH value of 61.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0474.
Aceso Life Science Group Limited Peers Comparison
Overall Rating
- HK:047451Neutral
HK:232747Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0474 | Aceso Life Science Group Limited | 0.14 | 0.04 | 40.00% | |
| HK:2327 | Meilleure Health International Industry Group Limited | 0.17 | -0.11 | -39.21% |
Aceso Life Science Group Limited Corporate Events
Aceso Life Science Scraps Major Share Subscription Deal, Cites Unmet Conditions
Aceso Life Science Group Limited has terminated a previously announced connected and major transaction involving a subscription of shares and the issuance of consideration shares under a specific mandate. The termination follows the parties’ assessme...
Aceso Life Science Wins Unanimous Shareholder Backing for AGM Resolutions
Shareholders of Aceso Life Science Group Limited unanimously approved all ordinary resolutions at the annual general meeting held on 16 September 2026. The poll-based voting covered receipt of the audited financial statements for the year ended 31 Ma...
Aceso Life Science details fair value losses on investment portfolio
Aceso Life Science Group Limited has detailed the composition of its financial assets measured at fair value through other comprehensive income as at 31 March 2026, highlighting minority stakes in securities trading, property investment, and financia...
Aceso Life Science Sets 2026 AGM to Renew Mandates and Expand Share Issuance Authority
Aceso Life Science Group Limited, a Cayman-incorporated company listed in Hong Kong under stock code 00474, operates in the life sciences sector with a focus on health-related businesses and investment in healthcare markets. Its governance framework...
Aceso Life Science to Resume Trading in Hong Kong After Publishing Delayed 2026 Results
Aceso Life Science Group Limited, a Cayman Islands-incorporated life sciences company listed in Hong Kong, operates under the oversight of a mixed board of executive, non-executive and independent non-executive directors. Its shares are traded on the...
Aceso Life Science Swings to Annual Profit on Discontinued Operations Gain
Aceso Life Science Group Limited, a Hong Kong-listed life sciences-focused investment and operating group, derives its results from a combination of core operations and valuation changes in investment properties and financial assets. The company’s di...
Aceso Life Science Delays Dispatch of Subscription Agreement Circular Again
Aceso Life Science Group Limited has announced a further delay in sending a shareholder circular related to a Subscription Agreement and the planned issuance of consideration shares under a specific mandate. The circular, which will include detailed...
Aceso Life Science Sets Board Date as Share Trading Remains Suspended Pending Results
Aceso Life Science Group Limited has scheduled a board meeting for 13 August 2026 in Hong Kong to approve and publish its audited final results for the year ended 31 March 2026 and to consider whether to recommend a final dividend. The timing and out...
Aceso Life Science Signals Profit on Subsidiary Disposal as Trading Stays Suspended
Aceso Life Science Group Limited has issued a positive profit alert, indicating it expects to report a profit of about HK$336 million for the year ended 31 March 2026, compared with a loss of approximately HK$1,017 million a year earlier. The turnaro...
Aceso Life Science Delays Dispatch of Subscription Agreement Circular to Shareholders
Aceso Life Science Group Limited has announced a further delay in sending a shareholder circular related to a Subscription Agreement and the proposed issue of consideration shares under a specific mandate. The circular, which will include reports fro...
Aceso Life Science Delays 2026 Results, Faces Trading Suspension in Hong Kong
Aceso Life Science Group Limited has announced it will miss the 30 June 2026 deadline to publish its audited annual results for the year ended 31 March 2026, citing the need for additional time to collect valuation data for certain financial assets,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 29, 2026